Richard Haubrich, MD is Vice President, Medical Affairs Research at Gilead Sciences. He oversees phase 3b and 4 Medical Affairs research across therapeutic areas including working with teams on Gilead sponsored studies and overseeing the portfolio of Investigator Sponsored and Collaborative studies. He also leads the Medical Affairs Research team that focuses on Observational studies. Dr. Haubrich is Professor Emeritus of Medicine, Division of Infectious Diseases at the University of California, San Diego, where he conducted HIV clinical research with the ACTG (AIDS Clinical Trial Group) and was the Principal Investigator for the California Collaborative Treatment Group. At UCSD, Dr. Haubrich’s research focused on antiretroviral therapy for HIV-infected patients, HIV drug resistance and PrEP. He has served on the FDA Antiviral Advisory Committee and the DHHS Panel on Antiretroviral Therapy for Adults and Adolescents. He has 194 peer reviewed publications.
11:05 AM - 11:50 AM (EDT)
Tuesday, June 15
The onset of COVID-19 required rapid development and availability of potential treatments. …